Brief: Phasebio Announces Publication Of Interim Results From Pivotal Reverse-It Phase 3 Trial Of Bentracimab In NEJM Evidence

PhaseBio Pharmaceuticals

01/12/2021 22:04

Dec 1 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO ANNOUNCES PUBLICATION OF INTERIM RESULTS FROM
PIVOTAL
REVERSE-IT PHASE 3 TRIAL OF BENTRACIMAB IN NEJM EVIDENCE
    * PHASEBIO PHARMACEUTICALS INC - BENTRACIMAB HAD NO
DRUG-RELATED
SERIOUS ADVERSE EVENTS
    * PHASEBIO PHARMACEUTICALS - GLOBAL PHASE 3 TRIAL OF
BENTRACIMAB
ACHIEVED BOTH PRIMARY REVERSAL ENDPOINT AND CO-PRIMARY ENDPOINT
OF CLINICAL HEMOSTASIS
    * PHASEBIO PHARMACEUTICALS INC - REMAIN ON TRACK TO SUBMIT
PLANNED
BIOLOGICS LICENSE APPLICATION TO U.S. FDA IN MID-2022 FOR
BENTRACIMAD

Source text for Eikon:  ID:nBwbcmQGBa 
Further company coverage:  PHAS.O